Immuneering Corp (IMRX) saw an uptrend of 3.41% in the recent trading with $8.49 being its most recent. The current price level -9.39% lower than the highest price of $9.37 marked by the stock while trading over the past 52-weeks, whereas it is 671.82% higher than the lowest price of $1.10 the company dropped to over past 52-weeks. The latest news story on IMRX appeared in (GlobeNewswire) under the title “Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Immuneering Corp Earnings – What Happened With IMRX
Coming around sales and income figures on IMRX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Immuneering Corp (IMRX) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 11.18% for net revenue.
IMRX – Immuneering Corp Stock Earnings Estimates
The perspective of Immuneering Corp (NASDAQ:IMRX)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.55 for stock’s EPS in the current quarter. Immuneering Corp (IMRX) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 11.18% for net revenue. Company’s EPS for the last quarter was -0.49.
Immuneering Corp – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 35.99 million. IMRX does have institutional investors; and they hold 10.54% of the stock.
As on 2024-06-30, CITADEL ADVISORS LLC was the top most holder in Immuneering Corp (NASDAQ:IMRX) with an ownership of 1.88 million shares of the company or 6.4083 of the stake worth $2.41 million. The filing also reveals VANGUARD GROUP INC as the second largest holder in the company with a control over 3.6442 of the outstanding shares. Its stake is worth $1.37 million for having 1.07 million shares in hand.
MILLENNIUM MANAGEMENT LLC also came holding a key position in the company during the recent quarter and it now holds 3.2455 of the outstanding shares. With this there are now 47.0 institutions which have possession in IMRX’s shares.
Key Metrics for IMRX
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Immuneering Corp has a debt to equity ratio of 0.14.
